Uterine Cancer Therapeutics & Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, others), By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan), By Region, and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 23.21 Billion
CAGR (2026-2031)	5.81%
Fastest Growing Segment	Endometrial Adenocarcinoma
Largest Market	North America
Market Size (2031)	USD 32.57 Billion

Market Overview

The Global Uterine Cancer Therapeutics & Diagnostics Market will grow from USD 23.21 Billion in 2025 to USD 32.57 Billion by 2031 at a 5.81% CAGR. Uterine cancer therapeutics and diagnostics encompass the pharmaceutical agents, surgical interventions, and screening technologies utilized for the detection and management of endometrial cancer and uterine sarcoma. The market is primarily driven by the rising prevalence of risk factors such as obesity and hormonal imbalances in postmenopausal women. Furthermore, the expansion of healthcare infrastructure and government initiatives promoting early screening programs significantly support the demand for effective treatment modalities.

Despite these drivers, the substantial cost associated with advanced immunotherapies and targeted drug delivery systems presents a significant barrier to market accessibility in developing regions. This economic challenge persists alongside the growing burden of the disease. According to the American Cancer Society, in 2024, an estimated 67,880 new cases of cancer of the uterine corpus were projected to be diagnosed in the United States. Consequently, financial constraints regarding long-term care remain a critical impediment to broader market expansion.

Key Market Drivers

The accelerated regulatory approval of novel targeted therapies and immunotherapies serves as a primary force propelling the uterine cancer therapeutics market. Regulatory bodies are increasingly granting clearances for immune checkpoint inhibitors, particularly for patients with mismatch repair deficient tumors, thereby transforming the standard of care for advanced endometrial carcinoma. These authorizations allow pharmaceutical developers to commercialize biologics that address unmet clinical needs in recurrent disease settings, shifting treatment paradigms away from traditional chemotherapy. According to the U.S. Food and Drug Administration, June 2024, in the 'FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer' press release, the efficacy of this new therapeutic regimen was evaluated in the DUO-E clinical trial involving 718 randomized patients. Such approvals directly incentivize further investment in the oncology pipeline.

Concurrently, the increasing global incidence of uterine malignancies necessitates the expansion of both diagnostic capabilities and therapeutic availability. This rise is often correlated with aging demographics and lifestyle factors, creating a sustained patient base requiring long-term management and surveillance. According to the Canadian Cancer Society, May 2024, in the 'Canadian Cancer Statistics 2024' report, projections indicated that 8,700 women in Canada would be diagnosed with uterine cancer within the year, highlighting the growing burden outside the United States. This escalating prevalence translates directly into commercial returns for key market players. According to GSK, in 2024, sales of the endometrial cancer treatment Jemperli reached £102 million in the third quarter alone, underscoring the rapid market adoption of newly approved immuno-oncology agents.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced immunotherapies and targeted drug delivery systems constitutes a primary restraint on the growth of the uterine cancer market. In regions with limited healthcare funding or inadequate insurance coverage, the high price of these pharmaceutical agents limits patient access and adoption rates. This economic barrier prevents the widespread implementation of newer treatment protocols, causing healthcare providers to rely on older, less expensive alternatives, thereby reducing the revenue potential for manufacturers of advanced therapeutics.

The impact of these financial constraints is magnified by the severity of the disease outcomes which demand effective intervention. According to the American Cancer Society, in 2024, approximately 13,250 deaths were expected to result from cancer of the uterine corpus in the United States. Despite the urgent clinical necessity indicated by such mortality figures, the prohibitive expenses linked to long-term management and novel drug regimens hinder market penetration. Consequently, the gap between clinical need and economic feasibility slows the overall commercial expansion of the sector.

Key Market Trends

The emergence of antibody-drug conjugates (ADCs) targeting HER2-positive disease marks a critical evolution in managing uterine malignancies, particularly serous carcinomas. ADCs deliver cytotoxic payloads directly to cancer cells via targeted antibodies, maximizing efficacy for patients with recurrent conditions who have exhausted standard treatment lines. This mechanism minimizes systemic toxicity compared to traditional approaches, offering a new therapeutic avenue for biomarker-defined patient subgroups. According to the U.S. Food and Drug Administration, April 2024, in the 'FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors' press release, the clinical validity of this class was substantiated by an objective response rate of 51.4% in the DESTINY-PanTumor02 trial. This shift towards biomarker-driven precision medicine addresses treatment gaps left by conventional chemotherapy.

The utilization of robot-assisted minimally invasive surgical techniques is reshaping the standard for hysterectomy and staging procedures. This approach reduces post-operative complications and enhances visualization compared to open laparotomy, facilitating the precise lymph node dissection essential for accurate disease staging. The adoption of these platforms allows surgeons to navigate complex anatomical structures with greater dexterity, which is particularly beneficial for obese patients often encountered in this demographic. According to Intuitive Surgical, October 2024, in the 'Intuitive Announces Third Quarter Earnings' report, worldwide da Vinci procedures grew approximately 18% year-over-year, underscoring the expanding reliance on robotic platforms in gynecologic oncology. This technological integration supports healthcare providers in optimizing surgical recovery times and managing increasing patient volumes.

Segmental Insights

The Endometrial Adenocarcinoma segment is identified as the fastest-growing category within the Global Uterine Cancer Therapeutics & Diagnostics Market. This growth is primarily attributed to the rising global incidence of this cancer type, which is strongly linked to obesity and aging demographics. Additionally, the market is expanding due to the development and regulatory approval of novel targeted therapies and immunotherapies by bodies such as the US Food and Drug Administration. These drivers, coupled with enhanced diagnostic screening rates, are fueling increased demand for specialized management solutions for this condition.

Regional Insights

North America maintains a leading position in the global uterine cancer therapeutics and diagnostics market due to the high incidence of endometrial cancer in the region. This dominance is reinforced by a robust healthcare infrastructure that supports early disease detection and the adoption of effective treatment regimens. Additionally, significant investments in research and development by established pharmaceutical manufacturers drive continuous product innovation. The proactive role of the U.S. Food and Drug Administration in granting approvals for new therapies further strengthens the regional market by ensuring timely patient access to clinical advancements.

Recent Developments

• In June 2025, Daiichi Sankyo announced that the first patient had been dosed in the DESTINY-Endometrial01 Phase 3 clinical trial evaluating its antibody-drug conjugate, trastuzumab deruxtecan. The study was initiated to assess the efficacy and safety of the therapeutic in combination with other agents as a first-line treatment for patients with mismatch repair proficient primary advanced or recurrent endometrial cancer that expresses HER2. This research development represented a strategic move to expand the application of the company’s technology into the uterine cancer market, aiming to offer new therapeutic alternatives for patients with specific biomarker profiles who previously had limited options.
• In February 2025, Acrivon Therapeutics announced that the U.S. Food and Drug Administration had granted Breakthrough Device Designation to its ACR-368 OncoSignature assay for identifying endometrial cancer patients who might benefit from treatment with the company's investigational drug, prexasertib. This diagnostic tool utilizes a proprietary approach to predict tumor sensitivity to the therapy, facilitating a personalized treatment strategy for individuals with this disease. The designation underscored the potential of the assay to provide effective treatment selection, addressing a critical unmet medical need in the management of patients with advanced forms of uterine cancer by matching them with the most appropriate therapeutic option.
• In August 2024, GSK received expanded approval from the U.S. Food and Drug Administration for its immuno-oncology drug, dostarlimab, in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This regulatory action broadened the indication to include all patients regardless of their mismatch repair status, establishing the therapy as the first immuno-oncology regimen to show a statistically significant overall survival benefit in the overall patient population for this condition. The approval was based on data from the Phase 3 RUBY trial, which highlighted the potential of the treatment to improve outcomes for a wider range of patients battling this gynecologic malignancy.
• In June 2024, Merck announced that the U.S. Food and Drug Administration had approved its anti-PD-1 therapy, pembrolizumab, in combination with carboplatin and paclitaxel, followed by the drug as a single agent, for treating adult patients with primary advanced or recurrent endometrial carcinoma. This regulatory milestone established the regimen as the first anti-PD-1-based therapy approved for this specific patient population regardless of mismatch repair status. The decision was supported by results from the Phase 3 KEYNOTE-868/NRG-GY018 trial, which demonstrated a statistically significant improvement in progression-free survival for patients receiving the immunotherapy combination compared to those treated with chemotherapy alone.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

By Cancer Type	By Therapeutics	By Diagnostics	By Region
Endometrial Adenocarcinoma Adenosquamous Carcinoma Papillary Serous Carcinoma Uterine Sarcoma	Surgery Immunotherapy Radiation Therapy Chemotherapy others	Biopsy Pelvic Ultrasound Hysteroscopy Dilation and Curettage CT scan	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type:

• Endometrial Adenocarcinoma
• Adenosquamous Carcinoma
• Papillary Serous Carcinoma
• Uterine Sarcoma

• Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics:

• Surgery
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• others

• Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics:

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• Dilation and Curettage
• CT scan

• Uterine Cancer Therapeutics & Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE